Recon: Judge bars compounders from making copies of Lilly’s weight loss drugs; PTAB invalidates two Moderna COVID vaccine patents

• Live updates: Marty Makary, Trump’s pick for FDA commissioner, testifies before Senate panel (STAT)
• Trump's FDA chief pick Makary to face overhauling agency, keeping Kennedy happy (Reuters)
• US judge ruling for FDA bars copies of Lilly weight loss drug (Reuters)
• Judge issues preliminary injunction blocking Trump cuts to NIH research overhead payments (STAT)
• How the race for the next obesity drug is shaping up (STAT)
• Pfizer, BioNTech Get PTAB To Invalidate Moderna Vaccine IP (Law 360) (Reuters)
• Jazz Pharmaceuticals to buy Chimerix for $935 million (Reuters)
• On path to likely confirmation as NIH director, Bhattacharya toes the party line (STAT)
• CDC invites back about 180 fired employees, including some who help fight outbreaks (STAT) (AP)

• No news is good news? Merck KGaA quiet on potential SpringWorks takeover (Endpoints)
• Bavarian Nordic CEO says it can take years to move pharma manufacturing to the US (Endpoints)
• Lilly, Pfizer invest in UK startup's seed round for neurodegeneration protein degraders (Endpoints)
• Novartis not panicking over potential US pharmaceutical tariffs, chairman says (Reuters)
• South African health agency calls for coal-fired power station phase-out (Reuters)
• Analysis: Competition Increases Amid China Medtech Market Growth (MedTech Insight)
• Galderma to discuss U.S. tariffs with retailers, sees "moving target" (Reuters)

• New radiopharmaceutical heading to the FDA after Phase 3 win (STAT)
• Roche/BioNTech experimental vaccine shows early promise in pancreatic cancer (Reuters)
• US FDA expands use of ARS Pharma's allergic reaction nasal spray in 15-30 kg patients (Reuters)
• Novo Nordisk to sell obesity drug Wegovy direct to patients at lower price (STAT) (Reuters)
• U.S. FDA places BioNTech's malaria vaccine study on clinical hold (Reuters)
• Novo Nordisk looks into starting GLP-1 drug trials for addiction (Endpoints)
• Denali stops some work on ALS drug after analysis showed no impact on key biomarker (Endpoints)
• Swiss biotech ends Phase 2 study in Alzheimer's shortly after Lilly and Biogen did the same (Endpoints)
• Italy's Amplifon posts 2024 margin below guidance, shares drop 12% (Reuters)

• Trump’s early actions imperil efforts to improve AI’s performance in medicine (STAT)
• Trump administration policies could create headwinds across healthcare: Fitch (MedTech Dive)
• Philips pulls endovascular implant from market after 20 injuries (MedTech Dive)
• Trump’s trade war heats up as countries retaliate against tariffs (MedTech Dive)
• Staar Surgical names Stephen Farrell as CEO (MedTech Dive)
• Medical device firms brace for effect of White House tariffs (MedTech Dive)

• Novo Nordisk will join legal row over FDA's removal of semaglutide from shortage list (Endpoints)
• Some malaria, TB programme cuts reversed by US, sources say (Reuters)
• Hospitals line up to sue Blue Cross, opting out of $2.8 bln settlement (Reuters)
• DOJ Position on Administrative Law Judges (FDA Law Blog)